Frontiers in Cellular Neuroscience (Mar 2019)
Pericytes Favor Oligodendrocyte Fate Choice in Adult Neural Stem Cells
- Maria Elena Silva,
- Maria Elena Silva,
- Maria Elena Silva,
- Simona Lange,
- Simona Lange,
- Bryan Hinrichsen,
- Bryan Hinrichsen,
- Amber R. Philp,
- Amber R. Philp,
- Carolina R. Reyes,
- Carolina R. Reyes,
- Diego Halabi,
- Diego Halabi,
- Josselyne B. Mansilla,
- Josselyne B. Mansilla,
- Peter Rotheneichner,
- Peter Rotheneichner,
- Alerie Guzman de la Fuente,
- Sebastien Couillard-Despres,
- Sebastien Couillard-Despres,
- Sebastien Couillard-Despres,
- Luis F. Bátiz,
- Robin J. M. Franklin,
- Ludwig Aigner,
- Ludwig Aigner,
- Ludwig Aigner,
- Francisco J. Rivera,
- Francisco J. Rivera,
- Francisco J. Rivera,
- Francisco J. Rivera
Affiliations
- Maria Elena Silva
- Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
- Maria Elena Silva
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Maria Elena Silva
- Institute of Pharmacy, Faculty of Sciences, Universidad Austral de Chile, Valdivia, Chile
- Simona Lange
- Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria
- Simona Lange
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria
- Bryan Hinrichsen
- Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
- Bryan Hinrichsen
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Amber R. Philp
- Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
- Amber R. Philp
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Carolina R. Reyes
- Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
- Carolina R. Reyes
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Diego Halabi
- Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
- Diego Halabi
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Josselyne B. Mansilla
- Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
- Josselyne B. Mansilla
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Peter Rotheneichner
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria
- Peter Rotheneichner
- Institute of Experimental Neuroregeneration, Paracelsus Medical University Salzburg, Salzburg, Austria
- Alerie Guzman de la Fuente
- Wellcome Trust and Medical Research Council (MRC) Cambridge Stem Cell Institute & Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
- Sebastien Couillard-Despres
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria
- Sebastien Couillard-Despres
- Institute of Experimental Neuroregeneration, Paracelsus Medical University Salzburg, Salzburg, Austria
- Sebastien Couillard-Despres
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Luis F. Bátiz
- Centro de Investigación Biomédica (CIB), Facultad de Medicina, Universidad de los Andes, Santiago, Chile
- Robin J. M. Franklin
- Wellcome Trust and Medical Research Council (MRC) Cambridge Stem Cell Institute & Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
- Ludwig Aigner
- Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria
- Ludwig Aigner
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria
- Ludwig Aigner
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Francisco J. Rivera
- Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
- Francisco J. Rivera
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Francisco J. Rivera
- Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria
- Francisco J. Rivera
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria
- DOI
- https://doi.org/10.3389/fncel.2019.00085
- Journal volume & issue
-
Vol. 13
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Upon demyelination, oligodendrocyte progenitor cells (OPCs) are activated and they proliferate, migrate and differentiate into myelin-producing oligodendrocytes. Besides OPCs, neural stem cells (NSCs) may respond to demyelination and generate oligodendrocytes. We have recently shown that CNS-resident pericytes (PCs) respond to demyelination, proliferate and secrete Laminin alpha2 (Lama2) that, in turn, enhances OPC differentiation. Here, we aimed to evaluate whether PCs influence the fate choice of NSCs in vitro, towards the production of new myelin-producing cells. Indeed, upon exposure to conditioned medium derived from PCs (PC-CM), the majority of NSCs gave rise to GalC- and myelin basic protein (MBP)-expressing oligodendrocytes at the expense of the generation of GFAP-positive astrocytes. Consistent with these findings, PC-CM induces an increase in the expression of the oligodendrocyte fate determinant Olig2, while the expression level of the astrocyte determinant ID2 is decreased. Finally, pre-incubation of PC-CM with an anti-Lama2 antibody prevented the generation of oligodendrocytes. Our findings indicate that PCs-derived Lama2 instructs NSCs to an oligodendrocyte fate choice favoring the generation of myelin-producing cells at the expense of astrocytes in vitro. Further studies aiming to reveal the role of PCs during remyelination may pave the way for the development of new therapies for the treatment of MS.
Keywords